Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXD5QP)

• Drug Name: SAR442257 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Malignant neoplasm	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMXD5QP

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclic ADP-ribose hydrolase 1 (CD38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daratumumab	DMKCIUZ	Multiple myeloma	2A83	Approved	[3]
Mezagitamab	DMWJXFO	Myasthenia gravis	8C6Y	Phase 2	[4]
CD38 and BCMA CAR-T Cells	DMFZS8A	Multiple myeloma	2A83	Phase 1/2	[5]
4SCAR19 and 4SCAR38	DMZKFU7	B-cell lymphoma	2A86	Phase 1/2	[6]
ISB 1342	DMG107N	Multiple myeloma	2A83	Phase 1/2	[7]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[8]
CD38 CAR T cells	DMPS3I6	Multiple myeloma	2A83	Phase 1/2	[9]
CD38 CAR-T Cell	DM0USBX	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[10]
SAR-650984	DMD20YH	Haematological malignancy	2B33.Y	Phase 1/2	[11]
MOR-202	DMR8AHJ	Multiple myeloma	2A83	Phase 1/2	[12]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[14]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[15]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[16]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[17]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[18]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[19]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[20]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[21]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[22]

Drug(s) Targeting T-cell-specific surface glycoprotein CD28 (CD28)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belatacept	DMXLYQF	Kidney transplant rejection	NE84	Approved	[23]
AB-103	DMPDQ8T	Necrotizing soft tissue infection	1B71	Phase 3	[24]
Lulizumab pegol	DMGWZ93	Systemic lupus erythematosus	4A40.0	Phase 2	[25]
REGN5678	DM0Y6WU	Prostate cancer	2C82.0	Phase 1/2	[26]
AU101	DMLAKPI	Osteosarcoma	2B51	Phase 1/2	[27]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[28]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[29]
CD19-CAR and CD28-CAR T Cells	DMUR1MN	Acute lymphoblastic leukaemia	2A85	Phase 1	[30]
RO7443904	DMSWZNU	Non-hodgkin lymphoma	2B33.5	Phase 1	[31]
RG6333	DM1BRF2	Non-hodgkin lymphoma	2B33.5	Phase 1	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclic ADP-ribose hydrolase 1 (CD38)	TTPURFN	CD38_HUMAN	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04401020) First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Sanofi.
• [3] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
• [4] Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325.
• [5] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [6] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [7] Clinical pipeline report, company report or official report of Ichnos Sciences.
• [8] ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
• [9] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [10] ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
• [11] Clinical pipeline report, company report or official report of Sanofi-Aventis.
• [12] Clinical pipeline report, company report or official report of MorphoSys.
• [13] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [14] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [15] Clinical pipeline report, company report or official report of Genmab.
• [16] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [17] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [18] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [19] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [20] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [21] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [22] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [23] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [25] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [26] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [27] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [28] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [29] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [30] ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
• [31] Clinical pipeline report, company report or official report of Genentch
• [32] Clinical pipeline report, company report or official report of Roche